IN2012DN03217A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN03217A IN2012DN03217A IN3217DEN2012A IN2012DN03217A IN 2012DN03217 A IN2012DN03217 A IN 2012DN03217A IN 3217DEN2012 A IN3217DEN2012 A IN 3217DEN2012A IN 2012DN03217 A IN2012DN03217 A IN 2012DN03217A
- Authority
- IN
- India
- Prior art keywords
- compounds
- compositions containing
- kinase
- pain
- cancer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108010083755 proto-oncogene proteins pim Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Enzymes And Modification Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24310409P | 2009-09-16 | 2009-09-16 | |
| PCT/US2010/049113 WO2011035019A1 (en) | 2009-09-16 | 2010-09-16 | Novel tricyclic protein kinase modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN03217A true IN2012DN03217A (cg-RX-API-DMAC7.html) | 2015-10-23 |
Family
ID=43757156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3217DEN2012 IN2012DN03217A (cg-RX-API-DMAC7.html) | 2009-09-16 | 2010-09-16 |
Country Status (13)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9342304B2 (en) | 2008-08-15 | 2016-05-17 | Apple Inc. | Processing vectors using wrapping increment and decrement instructions in the macroscalar architecture |
| US9335997B2 (en) | 2008-08-15 | 2016-05-10 | Apple Inc. | Processing vectors using a wrapping rotate previous instruction in the macroscalar architecture |
| US9335980B2 (en) | 2008-08-15 | 2016-05-10 | Apple Inc. | Processing vectors using wrapping propagate instructions in the macroscalar architecture |
| US8583904B2 (en) | 2008-08-15 | 2013-11-12 | Apple Inc. | Processing vectors using wrapping negation instructions in the macroscalar architecture |
| AU2012345888A1 (en) * | 2011-11-29 | 2014-05-29 | Baylor College Of Medicine | A method to enhance cognition |
| US9389860B2 (en) | 2012-04-02 | 2016-07-12 | Apple Inc. | Prediction optimizations for Macroscalar vector partitioning loops |
| MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
| WO2014110574A1 (en) | 2013-01-14 | 2014-07-17 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| UA121098C2 (uk) | 2013-01-15 | 2020-04-10 | Інсайт Холдинґс Корпорейшн | Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази |
| US9817663B2 (en) | 2013-03-19 | 2017-11-14 | Apple Inc. | Enhanced Macroscalar predicate operations |
| US9348589B2 (en) | 2013-03-19 | 2016-05-24 | Apple Inc. | Enhanced predicate registers having predicates corresponding to element widths |
| CN105492011A (zh) | 2013-04-08 | 2016-04-13 | 丹尼斯·M·布朗 | 不理想给药化学化合物的治疗增效 |
| WO2015027124A1 (en) | 2013-08-23 | 2015-02-26 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| CN105641707B (zh) * | 2014-11-11 | 2020-11-24 | 杭州多禧生物科技有限公司 | 细胞毒素分子同细胞结合受体分子的共轭体 |
| SG11201706146UA (en) | 2015-02-02 | 2017-08-30 | Forma Therapeutics Inc | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors |
| US10183934B2 (en) | 2015-02-02 | 2019-01-22 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors |
| CN107530353A (zh) * | 2015-03-04 | 2018-01-02 | 丹娜法伯癌症研究院 | Melk的三环激酶抑制剂和使用方法 |
| WO2016196244A1 (en) | 2015-05-29 | 2016-12-08 | Incyte Corporation | Pyridineamine compounds useful as pim kinase inhibitors |
| WO2017018060A1 (ja) * | 2015-07-27 | 2017-02-02 | 味の素株式会社 | システイン誘導体及びシステインスルホキシド誘導体の製造方法 |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EA201891620A1 (ru) | 2016-02-05 | 2019-02-28 | Денали Терапьютикс Инк. | Ингибиторы взаимодействующей с рецептором протеинкиназы 1 |
| WO2017218950A1 (en) | 2016-06-17 | 2017-12-21 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| EP3552017B1 (en) | 2016-12-09 | 2022-02-23 | Denali Therapeutics Inc. | Compounds useful as ripk1 inhibitors |
| EP3634370A4 (en) | 2017-06-06 | 2021-03-03 | Verrica Pharmaceuticals, Inc. | Treatment of cutaneous disorders |
| MX2019014908A (es) | 2017-06-15 | 2020-02-13 | Verrica Pharmaceuticals Inc | Dispositivos y metodos para el tratamiento de trastornos de la superficie corporal. |
| US11932606B2 (en) | 2017-07-31 | 2024-03-19 | The Regents Of The University Of California | Anti-cancer/anti-fibrosis compounds |
| IL273784B2 (en) | 2017-10-04 | 2024-02-01 | Verrica Pharmaceuticals Inc | Synthesis of cantharidin |
| CN109761902B (zh) * | 2017-11-09 | 2022-06-10 | 四川大学 | 6-菲啶酮衍生物及其制备方法和用途 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| EP3866804A4 (en) | 2018-10-19 | 2022-08-03 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
| CN109369528B (zh) * | 2018-11-26 | 2022-03-04 | 天津医科大学 | 三氟甲基取代环戊酮并喹啉化合物及药学上可接受的盐、其制备方法及应用 |
| EP4126846A1 (en) | 2020-03-30 | 2023-02-08 | Senhwa Biosciences, Inc. | Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis b and hepatitis d |
| EP4146205A4 (en) | 2020-05-05 | 2024-05-29 | Nuvalent, Inc. | HETEROAROMATIC MACROCYCLIC ETHERS AS CHEMOTHERAPEUTIC AGENTS |
| PE20230608A1 (es) | 2020-05-05 | 2023-04-13 | Nuvalent Inc | Quimioterapicos de eter macrociclico heteroaromatico |
| CN113004294B (zh) * | 2021-03-08 | 2023-01-17 | 温州大学新材料与产业技术研究院 | 一种四氢呋喃并1,4-二氢喹啉类化合物及其制备方法和应用 |
| CN118234725A (zh) | 2021-10-01 | 2024-06-21 | 纽威伦特公司 | 杂芳族大环醚化合物的固体形式、药物组合物及制备 |
| KR20240132504A (ko) | 2022-01-12 | 2024-09-03 | 데날리 테라퓨틱스 인크. | (s)-5-벤질-n-(5-메틸-4-옥소-2,3,4,5-테트라하이드로피리도 [3,2-b][1,4]옥사제핀-3-일)-4h-1,2,4-트리아졸-3-카복사미드의 결정질 형태 |
| HUE072274T2 (hu) | 2022-04-28 | 2025-11-28 | Xinthera Inc | Triciklusos PARP1 inhibitorok és alkalmazásaik |
| CN115819436B (zh) * | 2022-11-03 | 2023-09-05 | 淮阴师范学院 | 喹啉并环丁砜衍生物的制备方法 |
| CN116947879B (zh) * | 2023-07-25 | 2025-10-31 | 沈阳药科大学 | 一种bbi608类衍生物及其制备方法和在制备治疗stat3介导疾病的药物中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028624A2 (en) * | 2003-09-15 | 2005-03-31 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
| CA2974246C (en) * | 2006-09-01 | 2020-02-25 | Senhwa Biosciences, Inc. | Tricyclic heteroaryl compounds and their use as protein modulators |
-
2010
- 2010-09-16 IN IN3217DEN2012 patent/IN2012DN03217A/en unknown
- 2010-09-16 US US12/883,688 patent/US20110071136A1/en not_active Abandoned
- 2010-09-16 BR BR112012005970A patent/BR112012005970A2/pt not_active IP Right Cessation
- 2010-09-16 CA CA2774266A patent/CA2774266A1/en not_active Abandoned
- 2010-09-16 KR KR1020127009482A patent/KR20120104180A/ko not_active Withdrawn
- 2010-09-16 EP EP10817824A patent/EP2477493A1/en not_active Withdrawn
- 2010-09-16 JP JP2012529900A patent/JP2013505252A/ja active Pending
- 2010-09-16 CN CN2010800499607A patent/CN102647904A/zh active Pending
- 2010-09-16 SG SG2012018453A patent/SG179163A1/en unknown
- 2010-09-16 MX MX2012003322A patent/MX2012003322A/es not_active Application Discontinuation
- 2010-09-16 AU AU2010295619A patent/AU2010295619A1/en not_active Abandoned
- 2010-09-16 WO PCT/US2010/049113 patent/WO2011035019A1/en not_active Ceased
-
2012
- 2012-03-14 IL IL218631A patent/IL218631A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110071136A1 (en) | 2011-03-24 |
| KR20120104180A (ko) | 2012-09-20 |
| CA2774266A1 (en) | 2011-03-24 |
| JP2013505252A (ja) | 2013-02-14 |
| SG179163A1 (en) | 2012-05-30 |
| IL218631A0 (en) | 2012-05-31 |
| EP2477493A1 (en) | 2012-07-25 |
| WO2011035019A1 (en) | 2011-03-24 |
| AU2010295619A1 (en) | 2012-05-10 |
| MX2012003322A (es) | 2012-07-23 |
| CN102647904A (zh) | 2012-08-22 |
| BR112012005970A2 (pt) | 2015-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN03217A (cg-RX-API-DMAC7.html) | ||
| IN2012DN03213A (cg-RX-API-DMAC7.html) | ||
| IN2012DN03112A (cg-RX-API-DMAC7.html) | ||
| MX2011012369A (es) | Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa. | |
| MX2020009223A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MY188363A (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| MX366623B (es) | 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas. | |
| WO2012170827A3 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
| ZA201907613B (en) | Dosage regimes for the administration of an anti-cd19 adc | |
| PH12014501061B1 (en) | Tricyclic compounds, compositions comprising them and uses thereof | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2016009056A (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| PH12017501122A1 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| EA202190041A1 (ru) | Схемы дозирования для введения adc к cd19 | |
| HK1230956A1 (en) | Compositions and methods for treatment of abnormal cell growth | |
| WO2015024000A3 (en) | Mitochondrially-targeted electrophilic compounds for cancer treatment |